Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Leases Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Work In Process

Daily Values

Growth Metrics

Others

NovaBay Pharmaceuticals (NBY) Notes Payables (2017 - 2024)

Historic Notes Payables for NovaBay Pharmaceuticals (NBY) over the last 5 years, with Q4 2024 value amounting to $500000.0.

NovaBay Pharmaceuticals' Notes Payables changed N/A to $500000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $500000.0, marking a year-over-year change of. This contributed to the annual value of $500000.0 for FY2024, which is N/A changed from last year.
Latest data reveals that NovaBay Pharmaceuticals reported Notes Payables of $500000.0 as of Q4 2024.
NovaBay Pharmaceuticals' 5-year Notes Payables high stood at $1.2 million for Q1 2020, and its period low was $104000.0 during Q2 2020.